These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 24871500)

  • 21. Tigecycline in the treatment of ventilator-associated pneumonia: experience from the Latin American Tigecycline Use Registry.
    Curcio D; Castagnino J; Vazquez W; Vergara G; Curiale A;
    Infez Med; 2010 Mar; 18(1):27-34. PubMed ID: 20424523
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety and tolerability of tigecycline for the treatment of complicated skin and soft-tissue and intra-abdominal infections: an analysis based on five European observational studies.
    Guirao X; Sánchez García M; Bassetti M; Bodmann KF; Dupont H; Montravers P; Heizmann WR; Capparella MR; Simoneau D; Eckmann C
    J Antimicrob Chemother; 2013 Jul; 68 Suppl 2():ii37-44. PubMed ID: 23772045
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tigecycline Therapy for Nosocomial Pneumonia due to Carbapenem-Resistant Gram-Negative Bacteria in Critically Ill Patients Who Received Inappropriate Initial Antibiotic Treatment: A Retrospective Case Study.
    Wu X; Zhu Y; Chen Q; Gong L; Lin J; Lv D; Feng J
    Biomed Res Int; 2016; 2016():8395268. PubMed ID: 28044137
    [No Abstract]   [Full Text] [Related]  

  • 24. The combined use of tigecycline with high-dose colistin might not be associated with higher survival in critically ill patients with bacteraemia due to carbapenem-resistant Acinetobacter baumannii.
    Amat T; Gutiérrez-Pizarraya A; Machuca I; Gracia-Ahufinger I; Pérez-Nadales E; Torre-Giménez Á; Garnacho-Montero J; Cisneros JM; Torre-Cisneros J
    Clin Microbiol Infect; 2018 Jun; 24(6):630-634. PubMed ID: 28970161
    [TBL] [Abstract][Full Text] [Related]  

  • 25. High dose tigecycline in critically ill patients with severe infections due to multidrug-resistant bacteria.
    De Pascale G; Montini L; Pennisi M; Bernini V; Maviglia R; Bello G; Spanu T; Tumbarello M; Antonelli M
    Crit Care; 2014 May; 18(3):R90. PubMed ID: 24887101
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prospective, non-interventional, multi-centre trial of tigecycline in the treatment of severely ill patients with complicated infections: new insights into clinical results and treatment practice.
    Eckmann C; Heizmann WR; Leitner E; von Eiff C; Bodmann KF
    Chemotherapy; 2011; 57(4):275-84. PubMed ID: 21778715
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy of tigecycline for secondary Acinetobacter bacteremia and factors associated with treatment failure.
    Liou BH; Lee YT; Kuo SC; Liu PY; Fung CP
    Antimicrob Agents Chemother; 2015; 59(6):3637-40. PubMed ID: 25824230
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tigecycline treatment of critically ill patients: the LatinUser experience.
    Curcio D; Vargas SW; Ugarte Ubiergo S; Varón F; Rojas Suarez J; Paz Chávez C; Curiale A;
    Curr Clin Pharmacol; 2011 Feb; 6(1):18-25. PubMed ID: 21235466
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparable Efficacy of Tigecycline versus Colistin Therapy for Multidrug-Resistant and Extensively Drug-Resistant Acinetobacter baumannii Pneumonia in Critically Ill Patients.
    Kim WY; Moon JY; Huh JW; Choi SH; Lim CM; Koh Y; Chong YP; Hong SB
    PLoS One; 2016; 11(3):e0150642. PubMed ID: 26934182
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tigecycline for the treatment of patients with severe sepsis or septic shock: a drug use evaluation in a surgical intensive care unit.
    Swoboda S; Ober M; Hainer C; Lichtenstern C; Seiler C; Wendt C; Hoppe-Tichy T; Büchler M; Weigand MA
    J Antimicrob Chemother; 2008 Mar; 61(3):729-33. PubMed ID: 18222953
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Outcomes in patients infected with carbapenem-resistant Acinetobacter baumannii and treated with tigecycline alone or in combination therapy.
    Guner R; Hasanoglu I; Keske S; Kalem AK; Tasyaran MA
    Infection; 2011 Dec; 39(6):515-8. PubMed ID: 21789524
    [TBL] [Abstract][Full Text] [Related]  

  • 32. High-dose tigecycline for the treatment of nosocomial carbapenem-resistant Klebsiella pneumoniae bloodstream infections: A retrospective cohort study.
    Geng TT; Xu X; Huang M
    Medicine (Baltimore); 2018 Feb; 97(8):e9961. PubMed ID: 29465589
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prospective audit of bacteraemia management in a university hospital ICU using a general strategy of short-course monotherapy.
    Corona A; Wilson AP; Grassi M; Singer M
    J Antimicrob Chemother; 2004 Oct; 54(4):809-17. PubMed ID: 15375106
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Is there a future for tigecycline?
    Bassetti M; Poulakou G; Giamarellou H
    Intensive Care Med; 2014 Jul; 40(7):1039-45. PubMed ID: 24871501
    [No Abstract]   [Full Text] [Related]  

  • 35. Primary bacteraemia is associated with a higher mortality risk compared with pulmonary and intra-abdominal infections in patients with sepsis: a prospective observational cohort study.
    Mansur A; Klee Y; Popov AF; Erlenwein J; Ghadimi M; Beissbarth T; Bauer M; Hinz J
    BMJ Open; 2015 Jan; 5(1):e006616. PubMed ID: 25564146
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antibiotic treatment of infections due to carbapenem-resistant Enterobacteriaceae: systematic evaluation of the available evidence.
    Falagas ME; Lourida P; Poulikakos P; Rafailidis PI; Tansarli GS
    Antimicrob Agents Chemother; 2014; 58(2):654-63. PubMed ID: 24080646
    [TBL] [Abstract][Full Text] [Related]  

  • 37. 7 versus 14 days of antibiotic treatment for critically ill patients with bloodstream infection: a pilot randomized clinical trial.
    Daneman N; Rishu AH; Pinto R; Aslanian P; Bagshaw SM; Carignan A; Charbonney E; Coburn B; Cook DJ; Detsky ME; Dodek P; Hall R; Kumar A; Lamontagne F; Lauzier F; Marshall JC; Martin CM; McIntyre L; Muscedere J; Reynolds S; Sligl W; Stelfox HT; Wilcox ME; Fowler RA;
    Trials; 2018 Feb; 19(1):111. PubMed ID: 29452598
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The outcome of patients with severe and severe-complicated Clostridium difficile infection treated with tigecycline combination therapy: a retrospective observational study.
    Bishop EJ; Tiruvoipati R; Metcalfe J; Marshall C; Botha J; Kelley PG
    Intern Med J; 2018 Jun; 48(6):651-660. PubMed ID: 29363242
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of the clinical efficacy between tigecycline plus extended-infusion imipenem and sulbactam plus imipenem against ventilator-associated pneumonia with pneumonic extensively drug-resistant Acinetobacter baumannii bacteremia, and correlation of clinical efficacy with in vitro synergy tests.
    Jean SS; Hsieh TC; Hsu CW; Lee WS; Bai KJ; Lam C
    J Microbiol Immunol Infect; 2016 Dec; 49(6):924-933. PubMed ID: 26341302
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tigecycline in carbapenem-resistant Acinetobacter baumannii bacteraemia: susceptibility and clinical outcome.
    Kim NH; Hwang JH; Song KH; Choe PG; Kim ES; Park SW; Kim HB; Kim NJ; Park WB; Oh MD
    Scand J Infect Dis; 2013 Apr; 45(4):315-9. PubMed ID: 23113680
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.